Lepu Biopharma Co Ltd
HKEX:2157
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lepu Biopharma Co Ltd
HKEX:2157
|
CN |
|
National Grid PLC
LSE:NG
|
UK |
|
A
|
Agrana Beteiligungs AG
VSE:AGR
|
AT |
|
N4 Pharma PLC
LSE:N4P
|
UK |
|
AssetMark Financial Holdings Inc
NYSE:AMK
|
US |
Lepu Biopharma Co Ltd
Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.
Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.
